Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06510374 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

454

Enrollment

INDUSTRY

Sponsor class

Conditions

Intermediate Risk Non-Muscle Invasive Bladder Cancer

Interventions

DRUG: Nadofaragene Firadenovec

Sponsor

Ferring Pharmaceuticals